Ignite Creation Date:
2024-05-06 @ 12:22 PM
Last Modification Date:
2024-10-26 @ 12:58 PM
Study NCT ID:
NCT03746275
Status:
COMPLETED
Last Update Posted:
2022-05-02
First Post:
2018-11-01
Brief Title:
Study to Gain Insights in Treatment Patterns and Outcomes in Patients With Atherosclerosis Prescribed to Xarelto in Combination With Acetylsalicylic Acid
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
Xarelto Acetylsalicylic Acid Treatment Patterns and Outcomes in Patients With Atherosclerosis A Non-interventional Study
Status:
COMPLETED
Status Verified Date:
2022-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
XATOA
Brief Summary:
In this study researchers want to gain more information on treatment patterns of patients treated with Xarelto in combination with acetylsalicylic acid ASA Both drugs reduce the risk of blood clots via different pathways The study will enroll adult patients suffering from coronary artery disease narrowing or blockage of vessels that supply the heart with blood or peripheral artery disease narrowing or blockage of vessels that supply the legs or head with blood The study will focus on information on when and why physicians are starting to treat patients with Xarelto in addition to ASA treatment duration reasons to discontinue treatment and previous therapies The study will also look into treatment outcomes for patients being treated with a combination of Xarelto and ASA by their physicians
Detailed Description:
The study aims to collect real-world data on treatment patterns and decision points for treatment in patients with coronary artery disease CAD and or peripheral artery disease PAD treated with rivaroxaban 25 mg twice daily for the prevention of major cardiovascular events in adult patients with CAD at high risk of ischemic events and or documented PAD and to describe outcomes of an antithrombotic regime based on dual pathway inhibition vascular dose of rivaroxaban 25 mg twice daily plus low-dose ASA once daily across the broad range of patient risk profiles encountered in routine clinical practice
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None